Q&A

A Q&A: Manufacturing Dry Powder Inhaled Formulations By Spray Drying

iStock-1277148522-cancer

With lung cancer making up 25% of the total cancer deaths in the U.S. and worldwide, finding effective therapies to treat this global killer is critical.1 Inhalation delivery systems can offer improved efficacy and other patient benefits but only if particles are manufactured within the correct size and diameter. Spray drying, a highly scalable technique that is suitable for a wide range of APIs, can break particles down into the appropriate size. Understanding the spray-drying process and what challenges you could encounter when executing it is an important step in using this enabling technology for lung cancer indications.

Kimberly Shepard, Ph.D., principal engineer in R&D at Lonza Pharma & Biotech, presented the webinar, Local Delivery for Treatment of Lung Cancer: Manufacturing formulations for dry powder inhaler by spray drying. In it, Dr. Shepard discussed how spray drying can be used to address many of the challenges associated with today’s late-stage lung cancer treatments. She also reviewed two case studies about the use of spray drying for the formulation of two FDA-approved lung cancer treatments and the improved efficacy observed as a result. The following Q&A session was held after this webinar, where Dr. Shepard was able to address attendee questions about the details of the presentation and case studies.

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: